Zacks Investment Research Lowers Singular Genomics Systems (NASDAQ:OMIC) to Hold

Singular Genomics Systems (NASDAQ:OMICGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Singular Genomics Systems Inc. is a life science technology company. It focused on delivering genomic technologies for the advancement of science and medicine. Singular Genomics Systems Inc. is based in LA JOLLA, Calif. “

Separately, The Goldman Sachs Group cut their price target on Singular Genomics Systems from $17.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, April 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Singular Genomics Systems currently has a consensus rating of “Buy” and an average price target of $18.10.

Shares of Singular Genomics Systems stock opened at $3.04 on Thursday. The firm has a market cap of $214.58 million and a price-to-earnings ratio of -1.51. The stock’s 50-day moving average is $5.15 and its 200-day moving average is $8.51. Singular Genomics Systems has a one year low of $3.00 and a one year high of $33.37. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.87 and a quick ratio of 35.18.

Singular Genomics Systems (NASDAQ:OMICGet Rating) last issued its quarterly earnings results on Wednesday, March 2nd. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.08. On average, equities analysts expect that Singular Genomics Systems will post -1.47 EPS for the current year.

Large investors have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC acquired a new stake in shares of Singular Genomics Systems in the fourth quarter valued at about $57,000. Geode Capital Management LLC increased its position in shares of Singular Genomics Systems by 257.2% in the third quarter. Geode Capital Management LLC now owns 136,281 shares of the company’s stock valued at $1,524,000 after acquiring an additional 98,132 shares during the last quarter. UBS Asset Management Americas Inc. increased its position in shares of Singular Genomics Systems by 18.1% in the third quarter. UBS Asset Management Americas Inc. now owns 609,847 shares of the company’s stock valued at $6,824,000 after acquiring an additional 93,589 shares during the last quarter. New York State Common Retirement Fund increased its position in Singular Genomics Systems by 25.8% during the third quarter. New York State Common Retirement Fund now owns 27,208 shares of the company’s stock worth $304,000 after buying an additional 5,575 shares during the last quarter. Finally, Millennium Management LLC increased its position in Singular Genomics Systems by 114.8% during the third quarter. Millennium Management LLC now owns 454,193 shares of the company’s stock worth $5,082,000 after buying an additional 242,771 shares during the last quarter. 59.24% of the stock is currently owned by institutional investors and hedge funds.

Singular Genomics Systems Company Profile (Get Rating)

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits.

Featured Stories

Get a free copy of the Zacks research report on Singular Genomics Systems (OMIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Singular Genomics Systems (NASDAQ:OMIC)

Receive News & Ratings for Singular Genomics Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Singular Genomics Systems and related companies with MarketBeat.com's FREE daily email newsletter.